Centrus Energy Shares Rise 11% Amid Uranium Rally and Record $3.9 Billion Contract Book
Record backlog and a $900 million government contract anchor the nuclear fuel supplier's position, but Q1 earnings missed and part of the backlog requires capital not yet committed.
Centrus Energy (NYSE: LEU) shares jumped 10.68% on Thursday (2026-07-30), extending a recovery that has gathered pace since the nuclear fuel supplier's bruising spring, when the stock fell 8.8% in early May 2026 after first-quarter results missed analyst expectations and forward earnings estimates were trimmed. The URA uranium ETF gained 5.16% on Friday (2026-07-31), reinforcing renewed appetite across the uranium complex.4,5,1
The bounce is being framed against a record order book. At the end of the first quarter of 2026, Centrus reported a $3.9 billion backlog stretching through 2040, with roughly $3.1 billion tied to its low-enriched uranium business. Washington's push to rebuild domestic nuclear fuel supply, partly in anticipation of a Russian uranium import ban taking effect in 2028, has translated into direct contract value: the Department of Energy awarded Centrus a multi-phase HALEU contract worth up to $900 million earlier in 2026.4,5,3
The quarterly financials show the gap between the contract story and current-period economics. Centrus generated $76.7 million in revenue and $10 million in GAAP net income for the quarter ended March 31, 2026, ending the period with approximately $1.8 billion in cash, cash equivalents, and restricted cash. Against trailing twelve-month revenue of $452.3 million, the stock's $3.64 billion market capitalisation implies a price-to-sales multiple of roughly eight times — a premium that builds in considerable execution.4,2
The backlog comes with a condition that bears scrutiny. Centrus has disclosed that part of the $3.9 billion total depends on securing additional public and private investment to bring new LEU production capacity online. In a policy environment shaped by Congressional appropriations and DOE discretion, that is a real contingency.2
Some institutional money has been moving in anyway. In a Securities and Exchange Commission filing dated May 14, 2026 (2026-05-14), RPG Investment Advisory, LLC disclosed a new 50,460-share position in Centrus, with a quarter-end value of $8.76 million, representing 1.06% of the fund's 13F reportable assets.2
Uranium spot prices were under pressure through much of the spring. Spot uranium edged down to $85.95 per pound around mid-May 2026, part of a multi-month retreat from January's highs, and Centrus shares fell 5.4% in that session, according to StockStory.1 The URA ETF's 5.16% gain on Friday (2026-07-31) suggests the sector is being repriced higher, though current physical uranium spot prices were not available at time of publication.
High-assay low-enriched uranium is what differentiates Centrus from a plain uranium-equity play. HALEU is required for advanced reactor designs that utilities and technology companies are exploring to power data centers, and the United States has depended heavily on Russian conversion and enrichment capacity to meet its supply needs. The DOE contract's multi-phase structure de-risks the development program in principle, though phased disbursements mean the full $900 million is contingent on hitting milestones.3,4
The gap between the long-dated backlog thesis and near-term financial delivery is what makes this stock hard to size with confidence. Analysts cut their forward estimates after the Q1 miss in early May 2026, and the stock spent weeks working through that adjustment. Thursday's (2026-07-30) rally suggests some of that repricing is done. What comes next depends on whether HALEU milestone payments stay on schedule, whether the LEU contract book converts to cash at the pace the backlog implies, and whether capital for new production capacity materialises on a useful timeline.1,4,3